Skip Navigation


BJA Advance Access originally published online on October 28, 2008
British Journal of Anaesthesia 2008 101(6):788-797; doi:10.1093/bja/aen308
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/6/788    most recent
aen308v1
Right arrow E-Letters: Submit a response to the article
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chen, C.
Right arrow Articles by Varin, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, C.
Right arrow Articles by Varin, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2008. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Dose-dependency of pharmacokinetic/pharmacodynamic parameters after intravenous bolus doses of cisatracurium

C. Chen, N. Yamaguchi and F. Varin*

Faculté de pharmacie, Université de Montréal, C.P. 6128, Succursale Centre-ville, Montréal, QC, Canada H3C 3J7

* Corresponding author. E-mail: france.varin{at}umontreal.ca

Background: Pharmacokinetic/pharmacodynamic (PK/PD) parameters of neuromuscular blocking agents (NMBAs) are generally assumed to be dose-independent. To our knowledge, there are very few clinical reports where the PK/PD parameters of a NMBA were derived separately for each dose group during a formal dose-ranging study. The primary objective of this study was to challenge a potential dose-dependency of cisatracurium PK/PD parameters by conducting a well-controlled experimental study.

Methods: Eight dogs were anaesthetized with pentobarbital and mechanically ventilated. Two doses of cisatracurium (1.5xED95 and 6xED95) were administered in a randomized cross-over design after an appropriate washout period. Neuromuscular function was monitored using train-of-four (TOF) stimulation. Arterial blood was sampled continuously for the first minute after cisatracurium injection and at frequent intervals thereafter. Cisatracurium plasma concentrations were determined by high performance liquid chromatography analysis. PK/PD modelling of individual data sets was performed with NONMEM using a non-parametric approach and a descriptive sigmoid Emax model.

Results: Cisatracurium PKs were linear over the dose range studied. Using non-parametric PK/PD analysis, mean values for plasma–effect compartment equilibration delay (ke0) were 0.0600 vs 0.1278 min–1 (P<0.05) and sensitivity (EC50) were 323 vs 235 ng ml–1 (P<0.05) for the high and low doses, respectively.

Conclusions: A dose-dependent effect on the PK/PD parameters of cisatracurium has important clinical implications as an accurate estimate of the EC50 is desirable. PK/PD parameters derived after intubating bolus doses of cisatracurium would be more reliable.

Keywords: pharmacodynamics, cisatracurium; pharmacokinetics, cisatracurium; pharmacokinetics, dose-dependency; pharmacokinetics, early


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


E-letters:

Read all E-letters

Dose-dependency of PK/PD parameters after intravenous bolus doses of cisatracurium
Christopher JR Parker
British Journal of Anaesthesia, 16 Dec 2008 [Full text]

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.